

# Correction to "Galectin-3: A Novel Blood Test for the Evaluation and Management of Patients With Heart Failure"

[Rev Cardiovasc Med. 2012;13(1):e52 doi: 10.3909/ricm131err]

© 2012 MedReviews®, LLC

In *Reviews in Cardiovascular Medicine*, Volume 12, Number 4 on page 208 [Rev Cardiovasc Med. 2011; 12(4):200-210 doi: 10.3909/ricm0624], a typographical error resulted in an incorrect value. In Figure 6, individuals considered low risk are those in whom the galectin-3 level is  $\leq 17.8$  ng/mL, not  $\leq 7.8$  ng/mL. The correct figure appears below.

The editorial staff of *Reviews in Cardiovascular Medicine* carefully reviews each issue, attempting to ensure that all of the information presented is correct and complete. Occasionally, however, something gets past us and makes it into print. We apologize for any inconvenience this error may have caused you.




Figure 6. Evidence-based algorithm for the measurement of galectin-3 in patients with HF encountered either in the hospital or office setting. HF, heart failure; Mgt, management; NT-proBNP, N-terminal pro-B-type natriuretic peptide.